• About
  • Masthead
  • License Content
  • Advertise
  • Submit Press Release
  • RSS/Email List
  • 2MM Podcast
  • Write for us
  • Contact Us
2 Minute Medicine
No Result
View All Result

No products in the cart.

SUBSCRIBE
  • Specialties
    • All Specialties, All Recent Reports
    • Cardiology
    • Chronic Disease
    • Dermatology
    • Emergency
    • Endocrinology
    • Gastroenterology
    • Imaging and Intervention
    • Infectious Disease
    • Nephrology
    • Neurology
    • Obstetrics
    • Oncology
    • Ophthalmology
    • Pediatrics
    • Pharma
    • Preclinical
    • Psychiatry
    • Public Health
    • Pulmonology
    • Rheumatology
    • Surgery
  • AI Roundup
  • Pharma
  • The Scan+
  • Classics™+
    • 2MM+ Online Access
    • Paperback and Ebook
  • Rewinds
  • Visual
  • Podcasts
  • Partners
    • License Content
    • Submit Press Release
    • Advertise with Us
  • Account
    • Subscribe
    • Sign-in
    • My account
2 Minute Medicine
  • Specialties
    • All Specialties, All Recent Reports
    • Cardiology
    • Chronic Disease
    • Dermatology
    • Emergency
    • Endocrinology
    • Gastroenterology
    • Imaging and Intervention
    • Infectious Disease
    • Nephrology
    • Neurology
    • Obstetrics
    • Oncology
    • Ophthalmology
    • Pediatrics
    • Pharma
    • Preclinical
    • Psychiatry
    • Public Health
    • Pulmonology
    • Rheumatology
    • Surgery
  • AI Roundup
  • Pharma
  • The Scan+
  • Classics™+
    • 2MM+ Online Access
    • Paperback and Ebook
  • Rewinds
  • Visual
  • Podcasts
  • Partners
    • License Content
    • Submit Press Release
    • Advertise with Us
  • Account
    • Subscribe
    • Sign-in
    • My account
SUBSCRIBE
2 Minute Medicine
Subscribe
Home All Specialties Chronic Disease

Amoxicillin-clavulanate not associated with improved survival outcomes in patients with severe alcohol-related hepatitis receiving prednisolone

byZoya GomesandYuchen Dai
May 29, 2023
in Chronic Disease, Gastroenterology
Reading Time: 3 mins read
0
Share on FacebookShare on Twitter

1. In this randomized clinical trial, among 284 patients with severe alcohol-related hepatitis, mortality at 60 days was 17.3% in the amoxicillin-clavulanate group, compared with 21.3% in the placebo group.

2. Infection rates at 60 days were significantly lower in the amoxicillin-clavulanate group at 29.7%, compared with the placebo group at 41.5%.

Evidence Rating Level: 1 (Excellent)

Study Rundown: Severe alcohol-related hepatitis is associated with a mortality rate as high as 30% at 2-month follow-up. To improve mortality rates, oral prednisone is given to patients with severe alcohol-related hepatitis. However, despite receiving corticosteroid treatment, approximately 30% of patients with severe alcohol-related hepatitis will develop a bacterial or fungal infection. The benefits of prophylactic antibiotics for hospitalized patients with severe alcohol-related hepatitis remain unclear. Hence, this study aimed to determine the efficacy of amoxicillin-clavulanate, compared with placebo, on mortality in patients hospitalized with severe alcohol-related hepatitis being treated with prednisolone. A total of 292 patients were randomized in a 1:1 allocation to receive prednisolone combined with amoxicillin-clavulanate (n=145) or prednisolone combined with placebo (n=147), of which 284 were analyzed. The primary outcome was all-cause mortality at 60 days. No significant difference in 60-day mortality was found between patients randomized to amoxicillin-clavulanate and placebo. The most common serious adverse events were liver failure, infections, and gastrointestinal disorders. A limitation of this study was the fixed duration for antibiotic administration, as a longer or shorter duration of antibiotics may have been associated with a different outcome. Strengths, however, were that the study followed a rigorous methodology and performed an in-depth statistical analysis.  Overall, this study found that in patients hospitalized with severe alcohol-related hepatitis, amoxicillin-clavulanate combined with prednisolone was not associated with an improvement in 60-day survival compared with placebo.

Click to read the study in JAMA

Click to read an accompanying editorial in JAMA

RELATED REPORTS

#Visual Abstract: Targeted Agents Combined with CHOP Increased Response Rates for Peripheral T-Cell Lymphoma

Evaluating pediatric sinus antibiotics: effectiveness and safety comparison

#VisualAbstract: Addition of amoxicillin-clavulanate to prednisolone did not improve survival in patients with severe alcohol-related hepatitis

Relevant Reading: Corticosteroids reduce risk of death within 28 days for patients with severe alcoholic hepatitis, compared with pentoxifylline or placebo – a meta-analysis of individual data from controlled trials

In-Depth [randomized controlled trial]: This study investigated the efficacy of amoxicillin-clavulanate, compared with placebo, in patients hospitalized with severe alcohol-related hepatitis treated with prednisolone. The primary outcome of this study was all-cause mortality at 60 days. Secondary outcomes included all-cause mortality at 90 and 180 days, incidence of infection, incidence of hepatorenal syndrome, and proportion of participants with a MELD score less than 17 at 60 days, and proportion of patients with a Lille score less than 0.45 at 7 days. A total of 292 patients (mean age, 52.8 [SD, 9.2] years; 80 [27.4%] women) were randomized (1:1 allocation) to receive prednisolone combined with amoxicillin-clavulanate (n=145) or placebo, of which 284 were analyzed. No significant difference in 60-day mortality was found between patients randomized to amoxicillin-clavulanate and placebo (17.3% in the amoxicillin-clavulanate group and 21.3% in the placebo group [P=.33] between-group difference, -4.7% [95% CI, -14.0% to 4.7%]; hazard ratio, 0.77 [95% CI, 0.45-1.31]). Rates of infection at 60-days were significantly lower in the amoxicillin-clavulanate group (29.7% vs 41.5%; mean difference, -11.8% [95% CI, -23.0% to -0.7%]; subhazard ratio, 0.62; [95% CI, 0.41 – 0.9]; P = .02). No significant differences were identified in the remaining 3 secondary outcomes. At 60-day follow-up, patients reported 230 adverse events, of which 68 were in the amoxicillin-clavulanate group and 77 were in the placebo group.

Image: PD

©2023 2 Minute Medicine, Inc. All rights reserved. No works may be reproduced without expressed written consent from 2 Minute Medicine, Inc. Inquire about licensing here. No article should be construed as medical advice and is not intended as such by the authors or by 2 Minute Medicine, Inc.

Tags: alcoholic hepatitisamoxicillin–clavulanateprednisolone
Previous Post

HIV status does not impact mpox treatment with tecovirimat

Next Post

Death anxiety may impact several clinical parameters in cancer patients receiving palliative care

RelatedReports

#Visual Abstract: Targeted Agents Combined with CHOP Increased Response Rates for Peripheral T-Cell Lymphoma
StudyGraphics

#Visual Abstract: Targeted Agents Combined with CHOP Increased Response Rates for Peripheral T-Cell Lymphoma

August 8, 2024
Patient Basics: Acute Sinusitis
Infectious Disease

Evaluating pediatric sinus antibiotics: effectiveness and safety comparison

November 8, 2023
#VisualAbstract: Addition of amoxicillin-clavulanate to prednisolone did not improve survival in patients with severe alcohol-related hepatitis
StudyGraphics

#VisualAbstract: Addition of amoxicillin-clavulanate to prednisolone did not improve survival in patients with severe alcohol-related hepatitis

May 9, 2023
#VisualAbstract: Sirolimus plus prednisolone was superior to sirolimus monotherapy in treating patients with kaposiform hemangioendothelioma
StudyGraphics

#VisualAbstract: Sirolimus plus prednisolone was superior to sirolimus monotherapy in treating patients with kaposiform hemangioendothelioma

April 1, 2022
Next Post
Increased risk of stillbirth recurrence after a previous stillbirth

Death anxiety may impact several clinical parameters in cancer patients receiving palliative care

The Scan by 2 Minute Medicine®:  Ultra-Trail du Mont-Blanc, Taylor Swift, NBA rookie Chet Holmgren and Magic Mushrooms!

The Scan by 2 Minute Medicine®: Over the Counter Birth Control, The Promise of the Pancreatic Cancer Vaccine, and Montana Bans TikTok!

#VisualAbstract: Dupilumab for COPD with Type 2 Inflammation Indicated by Eosinophil Counts

#VisualAbstract: Dupilumab for COPD with Type 2 Inflammation Indicated by Eosinophil Counts

2 Minute Medicine® is an award winning, physician-run, expert medical media company. Our content is curated, written and edited by practicing health professionals who have clinical and scientific expertise in their field of reporting. Our editorial management team is comprised of highly-trained MD physicians. Join numerous brands, companies, and hospitals who trust our licensed content.

Recent Reports

  • Weighted vests and resistance training confer similar outcomes for bone density in the elderly
  • Breast cancer survivors may have a lower risk of Alzheimer’s dementia
  • Evaluating scar outcomes in pediatric burn patients following skin grafting 
License Content
Terms of Use | Disclaimer
Cookie Policy
Privacy Statement (EU)
Disclaimer

© 2021 2 Minute Medicine, Inc. - Physician-written medical news.

  • Specialties
    • All Specialties, All Recent Reports
    • Cardiology
    • Chronic Disease
    • Dermatology
    • Emergency
    • Endocrinology
    • Gastroenterology
    • Imaging and Intervention
    • Infectious Disease
    • Nephrology
    • Neurology
    • Obstetrics
    • Oncology
    • Ophthalmology
    • Pediatrics
    • Pharma
    • Preclinical
    • Psychiatry
    • Public Health
    • Pulmonology
    • Rheumatology
    • Surgery
  • AI Roundup
  • Pharma
  • The Scan
  • Classics™
    • 2MM+ Online Access
    • Paperback and Ebook
  • Rewinds
  • Visual
  • Podcasts
  • Partners
    • License Content
    • Submit Press Release
    • Advertise with Us
  • Account
    • Subscribe
    • Sign-in
    • My account
No Result
View All Result

© 2021 2 Minute Medicine, Inc. - Physician-written medical news.